Category: Workers Comp

511 posts found

Drug Approvals Impacting Workers’ Comp

The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.

Among many findings, JAMA reports that 20% of deaths among those aged 25-34 were opioid-related.

Within the last month, laws have passed in Tennessee, Colorado, South Carolina, Oklahoma, and Hawaii.

Global spending on cancer therapies now exceeds $133 billion.

Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.

A newly released draft guidance encourages the development of more sustained-release buprenorphine products.

In-depth reports for 16 different states examine medical payments, costs, duration of disability, and more.

Senate Bill 336 passed with a 44-6 vote and is now headed to the House.

Kratom continues to grow in popularity as a drug for pain and opioid withdrawal, despite concerns from the FDA, CDC and DEA.

In a special partner post with WorkCompWire, Healthesystems discusses developments in pain management, specialty drugs, and more.

If approved, Lucemyra (lofexidine) would be the first non-opioid drug approved to treat the symptoms of opioid withdrawal.

Healthesystems’ VP of Clinical Services discusses how workers’ comp is embracing a value-driven approach.

A new study analyzes the characteristics of chronic opioid use claims, while also examining opioid weaning data.

A Florida bill was recently signed into law, and states such as Arizona, Utah, Connecticut, and Oregon may follow suit.

Indiana and Kentucky signed off on formulary bills, while other states continue to make progress on their promised formularies.

Prev 1 2 3 4 5 … 31 32 33 34 35 Next